Free shipping on all orders over $ 500

Duvelisib (IPI-145)

Cat. No. M2073

All AbMole products are for research use only, cannot be used for human consumption.

Duvelisib (IPI-145) Structure
Synonym:

Duvelisib; INK1197

Size Price Availability Quantity
Free Sample (0.5-1 mg)  USD 0 In stock
10mM*1mL in DMSO USD 66  USD66 In stock
2mg USD 40  USD40 In stock
5mg USD 65  USD65 In stock
10mg USD 89  USD89 In stock
25mg USD 129  USD129 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Duvelisib (IPI-145) is a novel and selective PI3K δ/γ inhibitor with IC50 of 23 pM and 243 pM, respectively. IPI-145 prevents the activation of the PI3K delta/gamma-mediated signaling pathways which may lead to a reduction in cellular proliferation in PI3K delta/gamma-expressing tumor cells. Duvelisib (IPI-145) suppresses murine/human B-cell proliferation with EC50 of 0.5 nM/0.5 nM and also inhibits human T-cell proliferation with EC50 of 9.5 nM. IPI-145 was well tolerated and clinically active in a broad range of malignancies, including iNHL. IPI-145 (10 mg/kg) demonstrates dose-dependent effect in rat collagen induced arthritis (CIA) model.

Customer Product Validations & Biological Datas
Source Blood (2014). Figure 1. IPI-145
Method immunoblotting
Cell Lines CLL cells
Concentrations 0.01 to 1 μM
Incubation Time 24 h
Results Cell viability was measured every 24 hours; 0.25 to 5 μM IPI-145 exhibited concentration and timedependent induction of cytotoxicity in CLL.
Chemical Information
Molecular Weight 416.86
Formula C22H17ClN6O
CAS Number 1201438-56-3
Solubility (25°C) DMSO 40 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
References

[1] Anna Maria Frustaci, et al. Duvelisib for the treatment of chronic lymphocytic leukemia

[2] No authors listed. Duvelisib

[3] No authors listed. Duvelisib

[4] Ian W Flinn, et al. The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL

[5] Steven M Horwitz, et al. Activity of the PI3K-δ,γ inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma

Related PI3K Products
PI3Kγ inhibitor AZ2 

PI3Kγ inhibitor AZ2 is a highly selective PI3Kγ inhibitor (The pIC50 value for PI3Kγ is 9.3).

NIBR-17 

NIBR-17 is a pan-class I PI3K inhibitor with suitable pharmacokinetic properties and inhibits tumor growth.

RV-1729 

RV-1729 is an inhibitor of the phosphatidylinositol 3-kinase-δ (PI3Kδ).

Vulolisib 

Vulolisib is a potent and orally active phosphatidylinositol 3-kinase (PI3K) inhibitor, with IC50 values of 0.2 nM, 168 nM, 90 nM and 49 nM for PI3Kα, PI3Kβ, PI3Kγ and PI3Kδ, respectively.

Vps34-IN-4 

Vps34-IN-4 is a potent, selective, and orally active inhibitor of VPS34.

  Catalog
Abmole Inhibitor Catalog




Keywords: Duvelisib (IPI-145), Duvelisib; INK1197 supplier, PI3K, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.